II.
Physical and Chemical Properties (HSDB, 1994 (Friberg et al., 1986 ) Conversion factor not applicable
III. Major Uses or Sources
Vanadium pentoxide (V 2 O 5 ) is used as a catalyst in oxidation reactions in the production of sulfuric acid and plastics (Friberg et al., 1986) . It is also used as a mordant in dyeing, and as a component of photographic developer (Sax, 1984) . In the manufacture of glass, it is used as a depolarizer and inhibitor of UV light. V 2 O 5 is also released by the combustion of fossil fuels which contain small amounts of vanadium (NAS, 1974) .
IV. Acute Toxicity to Humans
Inhalation of V 2 O 5 fumes, released during the production of V 2 O 5 and during boiler cleaning, may result in irritation of the eyes and respiratory tract and in bronchospasm (Friberg et al., 1986) . The onset of symptoms occurs 1-6 days after exposure. Subsequent exposures to V 2 O 5 may result in increased severity of symptoms, most likely a result of sensitization (Zenz et al., 1962) . The eye irritation threshold is reported to be 0.5 mg/m³ (Reprotext, 1994) . The respiratory irritation threshold is reported to be below that of ocular irritation (Grant, 1986) .
High level acute exposures may result in CNS effects including paralysis, respiratory depression, convulsions, and death (Reprotext, 1994) . Zenz and Berg (1967) studied human sensory responses to controlled vanadium pentoxide exposures in 9 male volunteers. The men were exposed for one 8 hour period to 1.0, 0.25 or 0.1 mg/m 3 of V 2 O 5 . The 2 volunteers exposed to 1.0 mg/m 3 began to cough during the latter half of the exposure. The coughing persisted for 8 days after exposure. Five subjects were exposed to 0.25 mg/m 3 . On the morning following their exposure, all five unexpectedly developed a loose, productive cough which lasted 7 to 10 days. The 2 volunteers exposed to 0.1 mg/m 3 V 2 O 5 showed no symptoms during or immediately after exposure but within 24 hours they formed considerable mucus which subsided after 4 days. Workers exposed to 0.1-0.3 mg/m³ V 2 O 5 for a minimum of 6 months reported symptoms of eye, nose, and throat irritation and exhibited signs of pharyngeal infection, green tongue and wheezing or rales (Lewis, 1959) .
Predisposing Conditions for Vanadium Pentoxide Toxicity

Medical:
Persons with preexisting skin, eye, kidney, or respiratory conditions, especially chronic bronchitis or asthma, or other underlying cardiopulmonary disease may be more sensitive to the toxic effects of V 2 O 5 (Reprotext, 1999) .
Chemical:
Persons exposed simultaneously to phthalic anhydride and V 2 O 5 may be at greater risk for exacerbation of asthma. Persons exposed to other vanadium compounds may be more sensitive to the effects of V 2 O 5 exposure (Reprotext, 1999) .
V. Acute Toxicity to Laboratory Animals
Exposure to V 2 O 5 at a concentration of 500 mg/m³ for 23 minutes was found to be lethal in cats (Heimberger, 1929) . Gastroenteritis, pneumonitis, and pulmonary edema were observed at autopsy. An LC LO of 205 mg/m³ V 2 O 5 for a 7-hour exposure was reported for rabbits (Sjoberg, 1950) . Autopsy results revealed marked tracheitis, bronchopneumonia, and pulmonary edema. In this same study, rabbits exposed to 20-40 mg/m³ V 2 O 5 for 1 hour per day for "several months" (exact duration not specified) exhibited chronic rhinitis and tracheitis, emphysema and patches of lung atelectasis with bronchopneumonia.
Sixteen adult, male cynomolgus monkeys were acutely exposed by whole-body inhalation of V 2 O 5 dust (0.5 mg or 5.0 mg/m³) at 1 week intervals (Knecht et al., 1985) . Pulmonary function tests were performed one day after each inhalation exposure, and inflammation was studied by cytologic analysis of lower respiratory tract cells by bronchoalveolar lavage (BAL). Pre-exposure comparisons were used in place of controls. Reduction in air-flow in central and peripheral airways was noted without any change in parenchymal function. V 2 O 5 dust exposures led to a significant increase in the total cell counts recovered from the lungs by BAL, including very large increases in absolute number and relative percentage of polymorphonuclear leukocytes (PMN).
Rats (200-250 g) were intratracheally administered vanadium compounds or vehicle (as a control) (Pierce et al., 1996) . The soluble vanadium compounds NaVO 3 and VOSO 4 induced rapid and intense pulmonary inflammation and inflammatory cytokine mRNA expression while the less soluble V 2 O 5 was much less potent. Significant neutrophil influx was noted 24 hours after V 2 O 5 exposure and persisted for several days. Analysis of lavage fluid, BAL cells, and lung suggested rapid clearance of the V 2 O 5 from the lung surface and accumulation in BAL cells and lung tissue.
VI. Reproductive or Developmental Toxicity
No studies of reproductive toxicity in humans were available (Reprotext, 1994) .
Pregnant mice injected with a total dose of 28 µg V 2 O 5 (delivered as 0.15 ml of a 1.0 mM V 2 O 5 solution) on the eighth day of gestation exhibited a significant increase in number of fetuses with delayed skeletal ossification as compared to controls (Wide, 1984) . Additionally, six of the exposed fetuses had "broken spinal cords".
Pregnant Wistar rats were administered V 2 O 5 by intraperitoneal injections on days 6-15 (3 mg/kg/day) or 9-12 (5 mg/kg/day) of gestation (Zhang et al., 1993a) . Single doses (5 mg/kg/day) were also given on days 9, 10, or 11. Decreased maternal weight gain was noted. Effects observed included decreased weight gain, increased fetal mortality, decreased fetal weight, delayed bone ossification, subcutaneous hemorrhage, and dilation of lateral ventricles and renal pelvis. The greatest effects were noted from exposures on day 10. In a second study, pregnant Wistar rats were administered 0.33, 1, or 3 mg/kg-day over days 6-15 of gestation (Zhang et al., 1993b) . Adverse effects similar to that reported in the companion paper (Zhang et al., 1993a) were noted in the two higher dose groups but not in the low dose group.
Effects of vanadium pentoxide treatment on male mouse reproductive function were investigated (Altamirano-Lozano et al., 1996) . Sperm count, motility, and morphology were adversely affected, and decreased fertility rate was reported after intraperitoneal injection of 8.5 mg V 2 O 5 per kg body weight. 
VII. Derivation of Acute
Level Protective Against Severe Adverse Effects
No recommendation is made due to the limitations of the database.
Level Protective Against Life-threatening Effects
A NIOSH-IDLH of 35 mg/m³ has been presented, but the method for deriving this value was not reported (NIOSH, 1995) .
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